Retatrutide is one of the most closely watched compounds in metabolic peptide research, and the safety data from its published trials gets asked about constantly. This breakdown pulls directly from the Phase 2 trial published in the New England Journal of Medicine and cross-references it against the published safety data for semaglutide and tirzepatide, so researchers can see where the numbers actually come from rather than relying on secondhand summaries.
Everything below describes published clinical trial data for an investigational compound. Retatrutide is not FDA-approved, and research-grade retatrutide sold by peptide suppliers is intended strictly for in-vitro and laboratory research use, not for human or animal consumption.
What Is Retatrutide and How Does It Work?
Retatrutide (Eli Lilly's development code LY3437943) is a synthetic peptide studied as a triple hormone-receptor agonist. Rather than acting on a single metabolic pathway, it is designed to activate three receptors at once:
- GLP-1 (glucagon-like peptide-1) — slows gastric emptying and supports insulin secretion
- GIP (glucose-dependent insulinotropic polypeptide) — a second incretin pathway that may blunt some GLP-1-driven GI effects
- Glucagon receptor — the pathway that sets retatrutide apart from dual-agonist compounds, contributing to increased energy expenditure
For a deeper mechanism walkthrough, see our earlier explainer on triple-agonist research basics and the plain-English breakdown of how retatrutide differs from dual-agonist compounds like tirzepatide.
Inside the Phase 2 Safety Data
The primary safety dataset for retatrutide comes from a randomized, placebo-controlled Phase 2 trial (Jastreboff et al., 2023) that enrolled 338 adults with obesity, or overweight with at least one weight-related complication, and followed them for 48 weeks across four dose groups (1mg, 4mg, 8mg, and 12mg) plus placebo.
A few headline numbers set the stage for everything that follows:
- Adverse events of any kind were reported in 70% of the placebo group and 73–94% of retatrutide groups, with the highest rates in the 8mg and 12mg arms.
- Discontinuation due to adverse events ranged from 6% to 16% across retatrutide dose groups, compared with 0% in the placebo group.
- At 48 weeks, the 12mg group recorded a mean weight change of −24.2%, versus −2.1% for placebo — the efficacy signal that drives so much interest in the compound.
That last point matters for interpreting the safety data: side effects and efficacy in this class of compound are mechanistically linked. The same GLP-1 and GIP activity that suppresses appetite is also what drives the gastrointestinal side effect profile discussed below.
Reported Adverse Events: How Common Are They?
Gastrointestinal Effects During Dose Escalation
Consistent with the rest of the GLP-1/GIP class, gastrointestinal events were the most frequently reported adverse events in the trial, occurred primarily during dose escalation, and were described by trial investigators as predominantly mild to moderate. Reported rates in the 12mg group included:
| Adverse event | 12mg group | Trend |
|---|---|---|
| Nausea | ~47% | Dose-dependent, highest in 8mg/12mg arms |
| Diarrhea | ~33% | Dose-dependent |
| Abdominal pain | ~27% | Dose-dependent |
| Constipation | ~24% | Dose-dependent |
| Vomiting | ~21% | Dose-dependent |
The trial's authors noted that a lower initial dose (2mg rather than 4mg) partially mitigated these effects, and that GI events were the leading cause of treatment discontinuation.
Other Reported Effects
Beyond the GI profile, a few less-discussed findings from the trial are worth flagging because they rarely make it into secondary summaries:
- Heart rate increased in a dose-dependent manner, peaking around week 24 before declining through week 48 — a pattern also seen with other GLP-1-class compounds.
- Cutaneous hyperesthesia (heightened skin sensitivity) was reported in 7% of retatrutide-treated participants versus 1% on placebo. None of these events were classified as severe or serious.
- ALT elevations above three times the upper limit of normal occurred in 1% of participants, with mean liver enzyme levels unchanged or improved by week 48 overall.
Serious Adverse Events Reported in the Trial
Serious adverse events occurred at a similar rate in both the retatrutide and placebo groups — 4% in each — across 15 total events in 13 participants. That similarity matters: it suggests most serious events in the trial were not clearly attributable to the compound itself.
| Event | Reported detail |
|---|---|
| Acute pancreatitis | 1 case among trial participants; amylase/lipase elevations were otherwise asymptomatic |
| Gallbladder-related events | Cholecystitis in 1 participant; cholelithiasis in 2 participants |
| Renal events | 4 cases (~1%) across all trial groups combined |
| Cardiac | 1 case of prolonged QT interval, in a participant also taking an anti-nausea medication |
| Medullary thyroid cancer / C-cell hyperplasia | Zero cases reported |
| Clinically significant hypoglycemia | Zero cases reported |
One death occurred during the trial (drowning), and the site investigator assessed it as unrelated to retatrutide. It is included here for completeness, as full accounting of serious events is standard practice when reporting trial safety data.
On the positive side, the same 48-week dataset recorded meaningful metabolic improvements that are directly relevant to long-term cardiometabolic risk: 72% of participants with prediabetes at baseline reverted to normoglycemia (versus 22% on placebo), and roughly a third of participants in the higher-dose groups were able to discontinue at least one blood pressure medication.
How the Numbers Compare: Retatrutide vs Semaglutide vs Tirzepatide
Cross-compound comparisons are popular but easy to get wrong, mostly because the trials being compared ran for different lengths of time, used different dose-escalation schedules, and enrolled different populations. With that caveat firmly in place, here is what each compound's own pivotal trial reported at its respective top dose:
| Metric | Retatrutide 12mg (Phase 2, 48 wks) | Tirzepatide 15mg (SURMOUNT-1, 72 wks) | Semaglutide 2.4mg (STEP 1, 68 wks) |
|---|---|---|---|
| Nausea | ~47% | 31.0% | 44.2% |
| Diarrhea | ~33% | 23.0% | 29.7% |
| Vomiting | ~21% | 12.2% | 24.8% |
| Discontinuation (adverse events) | 6–16%* | 6.2% | 4.5% |
*Range reported across all retatrutide dose groups in the Phase 2 trial; the published data does not isolate a single discontinuation figure for the 12mg arm alone.
A few honest observations from that table: tirzepatide's dual GLP-1/GIP mechanism appears to carry the mildest GI burden of the three at each compound's top dose. Retatrutide's nausea and diarrhea rates run somewhat higher than both comparators in its Phase 2 data, though it's also the compound with the shortest trial duration and the least-refined dose-escalation schedule of the three — the trial authors themselves noted that "further refinement of the dose-escalation scheme for phase 3 trials may improve the side-effect profile." Semaglutide, despite years of real-world use, still reports the highest vomiting rate of the three at its approved dose.
Retatrutide's own Phase 3 program is still generating data, and any comparison should be revisited once that larger, longer dataset is published.
Populations Excluded or Flagged in the Trial Literature
Phase 2 and Phase 3 trial protocols for this compound class routinely exclude or flag specific populations, based on precautions carried over from the broader GLP-1/GIP/glucagon research literature rather than confirmed human findings specific to retatrutide:
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (a precaution originating from rodent studies, not confirmed in human data for this class)
- Personal history of pancreatitis
- Pregnancy, breastfeeding, or planned pregnancy during the trial period
- Severe pre-existing gastrointestinal disease, including gastroparesis or active inflammatory bowel disease
- Concurrent use of other glucose-lowering therapies, which introduces additional monitoring considerations around hypoglycemia risk
These exclusion criteria are documented in the trial's published protocol and supplementary materials, and they reflect the standard precautionary framework used across this entire receptor-agonist research category — not conclusions specific to retatrutide's own safety data.
Handling, Reconstitution, and Documentation for Research Use
None of the safety data above is meaningful if the research material itself is mishandled or improperly sourced. Lyophilized retatrutide requires reconstitution with bacteriostatic water and consistent cold-chain storage to remain stable for laboratory use. Our full walkthrough of proper technique lives in the peptide storage and reconstitution guide, and for vial-specific reconstitution math, see the research reference protocols for each available size: 5mg, 10mg, 20mg, and 30mg. The research volume helper is also useful for working through reconstitution and concentration math for any vial size.
Documentation matters just as much as handling technique. Third-party HPLC and mass spectrometry results confirm that a batch is what it claims to be and free of contaminants. Our guide on how to read a peptide COA covers what to look for, and CoreVials maintains batch documentation for eligible products, which can be checked using the COA lookup tool. Full sourcing and compliance expectations are outlined on our research compliance page. Current retatrutide vial sizes and availability are listed on the retatrutide product page.
What the Data Doesn't Yet Tell Us
The published retatrutide safety record currently extends to 48 weeks. That is enough to characterize the adjustment-period side effect profile described above, but it does not address multi-year safety, which is the most important open question for a compound intended for extended use.
Semaglutide and tirzepatide both have several additional years of trial and real-world monitoring behind them, and their long-term data (including 3-year tirzepatide follow-up showing no new safety signals) is the closest available reference point for the GLP-1 and GIP mechanisms retatrutide shares with them. The glucagon receptor component is the one pathway in retatrutide's mechanism without a comparably mature long-term dataset, since no other approved compound in this class combines it with GLP-1 and GIP activation. Phase 3 trials and post-approval monitoring, once available, will be what actually answers this question rather than extrapolation from related compounds.
Common Questions
Is retatrutide's published safety data better or worse than semaglutide's? On GI metrics, it depends on which effect you're comparing. Retatrutide's Phase 2 nausea rate (~47%) runs higher than semaglutide's STEP 1 rate (44.2%), while its vomiting rate (~21%) is lower than semaglutide's (24.8%). The trials also differ in length and dose-escalation design, which limits how directly the numbers can be compared.
Did the trial find any signal for thyroid cancer? No. The Phase 2 trial reported zero cases of medullary thyroid cancer or C-cell hyperplasia. The contraindication associated with this compound class originates from rodent studies and is carried forward as a precaution rather than a confirmed human finding.
How long did gastrointestinal side effects last in the trial? The published data describes GI events as occurring primarily during the dose-escalation period and as predominantly mild to moderate in severity, consistent with the broader pattern seen across GLP-1/GIP-class trials.
Is retatrutide FDA-approved? No. It remains an investigational compound in Phase 3 development. Research-grade retatrutide sold through peptide suppliers is intended for laboratory research only and is not a substitute for any approved medication.
Where can I read the original trial data? The primary source is the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023), linked in the references below, along with the current Phase 3 trial registrations.
Glossary
GLP-1 (Glucagon-Like Peptide-1): An incretin hormone that slows gastric emptying and supports insulin secretion. The primary mechanism shared across this entire compound class.
GIP (Glucose-Dependent Insulinotropic Polypeptide): A second incretin hormone; co-activation alongside GLP-1 is associated with a somewhat improved GI tolerability profile in published tirzepatide data.
Glucagon receptor: The third receptor targeted by retatrutide. In isolation it raises blood glucose, but combined with GLP-1 activity it appears to contribute to increased energy expenditure without a net hyperglycemic effect.
Triple agonist: A compound that activates three distinct receptor pathways simultaneously. Retatrutide is currently the only GIP/GLP-1/glucagon triple agonist in late-stage clinical development.
Serious adverse event (SAE): A trial-reporting classification for any adverse event resulting in death, hospitalization, permanent disability, or a similarly significant outcome, regardless of whether it is judged related to the study compound.
References
- Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. Read the study
- Frias, J.P., et al. Tirzepatide safety and efficacy data, SURMOUNT-1 trial. View trial registration
- Wilding, J.P.H., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity, STEP 1 Trial. New England Journal of Medicine. Read the study
- ClinicalTrials.gov. Retatrutide Phase 3 study registrations and ongoing trial listings. Search active trials
Research Use Only. Not for human or animal consumption.
